---
schema_version: "secwatch.filing_event.v1"
accession: "0001370053-23-000019"
form_type: "8-K"
ticker: "ANAB"
cik: "0001370053"
company_name: "ANAPTYSBIO, INC"
filed_at: "2023-03-01T23:59:59+00:00"
generated_at: "2026-06-18T17:23:31.296927+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AnaptysBio reports FY2022 net loss $128.7M; cash $584.2M; initiates Phase 2b trials for rosnilimab and ANB032

## Summary
- Net loss for Q4 2022 was $26.4M ($0.93 per share); full year net loss $128.7M ($4.57 per share), compared to $57.8M in 2021.
- Cash, cash equivalents and investments totaled $584.2M as of Dec 31, 2022; cash runway through year-end 2026 reiterated.
- Initiating global Phase 2b trial for rosnilimab (PD-1 agonist) in RA in Q3 2023; second Phase 2 trial in another indication by year-end 2023.
- Initiating global Phase 2b trial for ANB032 (BTLA agonist) in atopic dermatitis in Q2 2023; top-line data expected year-end 2024.
- Board authorized $50M stock repurchase plan in January 2023, expiring Dec 31, 2023.

## SEC filing metadata
- accession: 0001370053-23-000019
- form_type: 8-K
- ticker: ANAB
- cik: 0001370053
- company_name: ANAPTYSBIO, INC
- filed_at: 2023-03-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1370053/000137005323000019/0001370053-23-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1370053/000137005323000019/anab-20230301.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001370053-23-000019
- JSON: https://secwatch.observer/filing/0001370053-23-000019.json
- Plain text: https://secwatch.observer/filing/0001370053-23-000019.txt

## Key facts
- Earnings Releases
  ANAPTYSBIO, INC reported financial results for the three months and year ended December 31, 2022.
  - Period: the three months and year ended December 31, 2022
  - Result: reported results
  source text: On March 1, 2023, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the three months and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1370053/000137005323000019/0001370053-23-000019-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.